Literature DB >> 12900746

Pulmonary hypertension: work in progress.

Paul D Boyce1, Aaron B Waxman.   

Abstract

Pulmonary arterial hypertension is a rare disorder defined by mean pulmonary artery pressures that exceed 25 mm Hg at rest or are greater than 30 mm Hg with exercise. The mortality rate is high for untreated patients, mainly as a result of progressive right heart dysfunction. Pulmonary arterial hypertension has been historically classified as primary pulmonary hypertension or pulmonary hypertension resulting from an underlying disease process. Ongoing research in the nuclear medicine field holds great promise for understanding the pathophysiologic pathways for this condition, as well as the monitoring of the continually evolving therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900746     DOI: 10.1016/s1071-3581(03)00549-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  98 in total

1.  Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD.

Authors:  M A Higham; D Dawson; J Joshi; P Nihoyannopoulos; N W Morrell
Journal:  Eur Respir J       Date:  2001-03       Impact factor: 16.671

2.  [Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension].

Authors:  E Greiser
Journal:  Internist (Berl)       Date:  1973-09       Impact factor: 0.743

3.  Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure.

Authors:  K L Chan; P J Currie; J B Seward; D J Hagler; D D Mair; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

4.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.

Authors:  P J Currie; J B Seward; K L Chan; D A Fyfe; D J Hagler; D D Mair; G S Reeder; R A Nishimura; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

5.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

6.  Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation.

Authors:  A Homma; A Anzueto; J I Peters; I Susanto; E Sako; M Zabalgoitia; C L Bryan; S M Levine
Journal:  J Heart Lung Transplant       Date:  2001-08       Impact factor: 10.247

Review 7.  Outcome after pulmonary thromboendarterectomy.

Authors:  C J Archibald; W R Auger; P F Fedullo
Journal:  Semin Thorac Cardiovasc Surg       Date:  1999-04

8.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

9.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04

10.  Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).

Authors:  M Humbert; O Sanchez; M Fartoukh; J L Jagot; O Sitbon; G Simonneau
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.